ZA908134B - Esters of castanosperime in the treatment of cerebral malaria - Google Patents

Esters of castanosperime in the treatment of cerebral malaria

Info

Publication number
ZA908134B
ZA908134B ZA908134A ZA908134A ZA908134B ZA 908134 B ZA908134 B ZA 908134B ZA 908134 A ZA908134 A ZA 908134A ZA 908134 A ZA908134 A ZA 908134A ZA 908134 B ZA908134 B ZA 908134B
Authority
ZA
South Africa
Prior art keywords
cells
treatment
falciparum
esters
castanosperime
Prior art date
Application number
ZA908134A
Other languages
English (en)
Inventor
Alan Joseph Bitonti
Joseph Bitonti Alan
Peter Paul Mccann
Paul Mccann Peter
Albert Sjoerdsma
Sjoerdsma Albert
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA908134B publication Critical patent/ZA908134B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA908134A 1989-10-17 1990-10-11 Esters of castanosperime in the treatment of cerebral malaria ZA908134B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42286989A 1989-10-17 1989-10-17

Publications (1)

Publication Number Publication Date
ZA908134B true ZA908134B (en) 1991-07-31

Family

ID=23676762

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA908134A ZA908134B (en) 1989-10-17 1990-10-11 Esters of castanosperime in the treatment of cerebral malaria

Country Status (8)

Country Link
EP (1) EP0423728B1 (de)
JP (1) JPH03133930A (de)
KR (1) KR100188799B1 (de)
AT (1) ATE127017T1 (de)
AU (1) AU628228B2 (de)
DE (1) DE69021980T2 (de)
IE (1) IE67048B1 (de)
ZA (1) ZA908134B (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315276C (en) * 1987-07-02 1993-03-30 Paul S. Liu Castanospermine esters and glycosides
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
AU618838B2 (en) * 1988-08-10 1992-01-09 Praxis Pharmaceuticals, Inc. Use of castanospermine as an anti-inflammatory and immunosuppressant agent

Also Published As

Publication number Publication date
IE67048B1 (en) 1996-02-21
IE903711A1 (en) 1991-04-24
EP0423728A2 (de) 1991-04-24
JPH03133930A (ja) 1991-06-07
AU628228B2 (en) 1992-09-10
KR100188799B1 (ko) 1999-06-01
DE69021980D1 (de) 1995-10-05
KR910007529A (ko) 1991-05-30
DE69021980T2 (de) 1996-02-15
EP0423728B1 (de) 1995-08-30
EP0423728A3 (en) 1993-02-03
AU6453290A (en) 1991-04-26
ATE127017T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
CA2116238A1 (en) Oral 1 .alpha.-hydroxyprevitamin d
DE68915878D1 (de) Gefässkatheter.
DE68910383D1 (de) Selbstabschliessende intravaskuläre Kanüle.
DE68922887D1 (de) Zusammengesetzter Gefässkatheter.
DE3782840D1 (de) Arzneimittel mit verzoegerter freigabe.
GR3016980T3 (en) Antiviral use of compositions comprising EFAs and Interferon.
EP0283513A4 (de) Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen.
USD314824S (en) Blood centrifuge or the like
USD354354S (en) Automatic blood analyzer
ATE145659T1 (de) Plastisolzusammensetzungen
EP0300680A3 (de) Doppelsträngige RNS zur Korrektur von Abnormalitäten von zirkulierenden Immunkomplexen und der Monozytenfunktion
FI99087B (fi) Varjoainevalmisteet
AU6927087A (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- substituted-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters
USD338962S (en) Automatic blood analyser
ATE191341T1 (de) Tabletten mit thioctsäure bestimmter korngrösse
EP0423728A3 (en) Esters of castanospermine in the treatment of cerebral malaria
TW223589B (de)
NO881214L (no) Fremgangsmaate for fremstilling av farmasoeytisk preparat med virkning paa hjerte- og karsystemet.
DE59105478D1 (de) Copolymerisatlösungen auf der Basis von Additionsprodukten alpha,beta-ungesättigter Carbonsäure mit Glycidylestern und damit mischpolymerisierbarer alpha,beta-ungesättigter Monomerer.
EP0263174A4 (de) Erhöhte gefässperfusion nach verabreichung von lipiden.
EP0193164A3 (de) 2-Nitroxymethyl-6-chloropyridin enthaltende Arzneipräparate mit verzögerter Freisetzung, Verfahren zu deren Herstellung sowie deren Verwendung
DE59002503D1 (de) Niedermolekulare Polymerisate von Acrylsäureestern.
USD302086S (en) Cabinet railing
USD308702S (en) Game board
KR890000418A (ko) 신규의 퍼옥시드 모노머 및 그로부터의 폴리머